I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation
2026-07-23 15:15
•Thomas Niel •The Motley Fool
••••••••••• ••• Axe Capital view
Three Dividend Stocks Worth Doubling Up On Now
AbbVie, Chevron, and PepsiCo offer reliable income and growth despite market jitters.
When the market feels jittery, dividend stocks often provide a reliable anchor. AbbVie has shaken off patent worries with its immunology drugs like Skyrizi and Rinvoq, and it’s on track for double-digit revenue growth by 2026. Chevron’s almost 40-year streak of dividend hikes speaks volumes, and oil prices above $70 a barrel could keep its earnings growing at around 10% annually. PepsiCo stands out selling defensive brands internationally; its valuation is cheap compared to Coca-Cola despite a 54-year dividend ramp. These giants provide dependable cash flow in volatile times. South African investors might watch USD/ZAR closely here — the rand’s fluctuations can affect import-dependent companies and could also influence offshore earnings when repatriated. I’d treat these stocks as a defensive tilt rather than a full growth pivot. The view might falter if oil prices dive drastically or if global inflation spikes, hurting consumer spending. this is just my opinion and not financial advice
I would double my positions in AbbVie and Chevron for income stability and growth, and add PepsiCo as a defensive consumer play, watching USD/ZAR for currency risk.
- ABBV
- CVX
- PEP
- USD/ZAR
- Sharp fall in oil prices impacting Chevron
- Rand volatility affecting repatriated earnings
- Global inflation pressure reducing consumer spending
7/10
The article recommends three blue-chip dividend stocks as defensive investments during market uncertainty: AbbVie, benefiting from immunology therapy success and expected 10% revenue growth in 2026; Chevron, with nearly 40 years of consecutive dividend growth and potential 10% annualized earnings growth through 2030; and PepsiCo, trading at a discount with a 4.4% dividend yield and 54-year dividend increase streak despite recent market bearishness.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Thomas Niel
Categories: Rates, Equities, Earnings, M&A, Capital Returns, Commodities, Energy, Geopolitics, Technology, AI, Semiconductors
Tickers: ABBV, CVX, PEP
Sentiment: Positive - Strong rebound from patent expiration concerns due to successful immunology therapies (Skyrizi, Rinvoq); pending Apogee Therapeutics acquisition positions company for further growth; forecasts call for ~10% revenue growth and ~40% earnings growth in 2026; consistent annual dividend increases since 2013 spinoff. Nearly 40 years of consecutive dividend growth with potential to reach Dividend King status; game plan for capital discipline could deliver 10% annualized earnings growth through 2030 if Brent crude stays above $70/barrel; 3.75% forward dividend yield with 6% average annual growth over past five years.
Keywords: dividend stocks, defensive investing, blue-chip companies, dividend growth, immunology, energy sector, packaged food
Insights:
- ABBV: Positive: Strong rebound from patent expiration concerns due to successful immunology therapies (Skyrizi, Rinvoq); pending Apogee Therapeutics acquisition positions company for further growth; forecasts call for ~10% revenue growth and ~40% earnings growth in 2026; consistent annual dividend increases since 2013 spinoff.
- CVX: Positive: Nearly 40 years of consecutive dividend growth with potential to reach Dividend King status; game plan for capital discipline could deliver 10% annualized earnings growth through 2030 if Brent crude stays above $70/barrel; 3.75% forward dividend yield with 6% average annual growth over past five years.
- PEP: Positive: Trading at discount (18x forward earnings vs. Coca-Cola's 25x) despite market bearishness; already a Dividend King with 54-year dividend increase streak; 4.4% forward dividend yield; potential upside from tariff refunds and strong international results could offset recent U.S. market share concerns.